Showing posts with label Microscopic hematuria. Show all posts
Showing posts with label Microscopic hematuria. Show all posts

Saturday, April 8, 2017

Here are the top 5 posts this week.

 Mayo Clinic Tampon Test for detecting Endometrial Cancer at early stage
Mayo clinic expert Jamie N. Bakkum-Gamez, M.D. and her team are in the process of developing a simple screening test that can be done at home using a tampon. It is based on the concept of detecting tumor DNA hypermethylation in vaginal pool DNA picked up by ordinary tampon.

At last, a no surgery, no knife, noninvasive treatment for uterine fibroid receives European approval.
Mirabilis Medical, a Seattle based company received CE Mark authorization for marketing of the Mirabilis System for treatment of uterine fibroids throughout the European Union.  It also announced that it had received a green signal from US-FDA to begin its clinical studies in US.

Ethicon STRATAFIX™ Spiral Plus Devices transforms wound closure experience for surgeons.
It has launched Stratafix Spiral PDS Plus and Stratafix Spiral Monocryl Plus Knotless Tissue Control Devices that provides a unique edge over traditional suturing.

Test strips for point of care detection of cervical cancer: Reality in near future.
Researchers at Purdue are developing technology that could enable us to detect cervical cancer with low-cost, easy-to-use, lateral flow test strips that are very similar to home pregnancy tests.

ACOG updates guidelines on investigating microscopic hematuria in females.
The American College of Obstetricians and Gynecologists(ACOG)  and the American Urogynecologic Society (AUS) has updated its guidelines for low risk women presenting with microscopic hematuria.
The committee opinion was published online on March 30, 2017 ahead of print in Journal of Obstetrics and Gynecology.


Monday, April 3, 2017

ACOG updates guidelines on investigating microscopic hematuria in females.

courtesy: wn.com
Microscopic hematuria detected during urine analysis without any symptoms is an important clinical indicator of malignancy. Over the years, the definitions of microscopic hematuria have changed, but the data was primarily based on studies done on male patients.

The American College of Obstetricians and Gynecologists(ACOG)  and the American Urogynecologic Society (AUS) has updated its guidelines for low risk women presenting with microscopic hematuria.

The committee opinion was published online on March 30, 2017 ahead of print in Journal of Obstetrics and Gynecology.

Sex specific guidelines for microscopic hematuria were not available till now, although the differential diagnosis of microscopic hematuria varies considerably according to the sex of the patient.

Risk of urinary tract malignancies are considerably less in females.
In women older than 60 years, gross hematuria with a history of smoking is a strong predictor of urologic malignancy.

In women younger than 50 years, not presenting with gross hematuria with no history of smoking and fewer than 25 red blood cells per high-power field on microscopic urine examination the risk of urinary tract malignancy is less than .5%.

Evaluation of such patients is not cost effective and may result in more harm than benefit. Hence, the data supports changing the guidelines in low risk groups.

ACOG and AUS has recommended the organization formulating guidelines to analyze sex specific data and formulate sex specific guidelines.

In the meantime, ACOG and AUS recommend that women between 35-50 years of age, who do not have any symptoms or a history of smoking should undergo evaluation only if they have more than 25 red blood cells per high-power field.